MedTrace Logo

Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

NCT07683806 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2026-08-21

No results posted yet for this study

Summary

This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.

Conditions

Interventions

DRUG

Roflumilast Foam 0.3%

Roflumilast foam 0.3% is applied once daily for 8 weeks.

DRUG

Vehicle foam

Vehicle foam is applied once daily for 8 weeks.

Sponsors & Collaborators

  • Arcutis Biotherapeutics, Inc.

    collaborator INDUSTRY

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-24
Primary Completion
2027-06-30
Completion
2027-08-03

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07683806 on ClinicalTrials.gov